SGTA and C1QTNF6 |
small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha |
C1q and tumor necrosis factor related protein 6 |
|
|
|
|
|
|
SRC and WWOX |
SRC proto-oncogene, non-receptor tyrosine kinase |
WW domain containing oxidoreductase |
|
- Nuclear signaling by ERBB4
- Signaling by ERBB4
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|
|
SRC and SYK |
SRC proto-oncogene, non-receptor tyrosine kinase |
spleen tyrosine kinase |
|
- Signaling by the B Cell Receptor (BCR)
- FCERI mediated MAPK activation
- Platelet Aggregation (Plug Formation)
- DAP12 signaling
- Regulation of signaling by CBL
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- DAP12 interactions
- Integrin alphaIIb beta3 signaling
- Cytokine Signaling in Immune system
- Role of LAT2/NTAL/LAB on calcium mobilization
- Signaling by Interleukins
- Fc epsilon receptor (FCERI) signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- FCERI mediated Ca+2 mobilization
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
- Staurosporine
- N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
- 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
- 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
- 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
- Ellagic Acid
|
|
|
STAT3 and HNF1A |
signal transducer and activator of transcription 3 (acute-phase response factor) |
HNF1 homeobox A |
- Signaling by PDGF
- Signalling by NGF
- Signaling by FGFR in disease
- Cellular Senescence
- Interleukin-6 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Signaling by SCF-KIT
- Signaling by Interleukins
- Transcriptional regulation of pluripotent stem cells
- Downstream signal transduction
- Signaling by FGFR1 mutants
- Signalling to STAT3
- Signaling by FGFR mutants
- Signaling by FGFR1 fusion mutants
- POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
- Signaling by Leptin
- Growth hormone receptor signaling
|
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
|
|
|
|
SYK and HDAC9 |
spleen tyrosine kinase |
histone deacetylase 9 |
- Signaling by the B Cell Receptor (BCR)
- FCERI mediated MAPK activation
- Platelet Aggregation (Plug Formation)
- DAP12 signaling
- Regulation of signaling by CBL
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- DAP12 interactions
- Integrin alphaIIb beta3 signaling
- Cytokine Signaling in Immune system
- Role of LAT2/NTAL/LAB on calcium mobilization
- Signaling by Interleukins
- Fc epsilon receptor (FCERI) signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- FCERI mediated Ca+2 mobilization
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Staurosporine
- N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
- 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
- 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
- 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
- Ellagic Acid
|
|
|
|
SYK and FCRL3 |
spleen tyrosine kinase |
Fc receptor-like 3 |
- Signaling by the B Cell Receptor (BCR)
- FCERI mediated MAPK activation
- Platelet Aggregation (Plug Formation)
- DAP12 signaling
- Regulation of signaling by CBL
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- DAP12 interactions
- Integrin alphaIIb beta3 signaling
- Cytokine Signaling in Immune system
- Role of LAT2/NTAL/LAB on calcium mobilization
- Signaling by Interleukins
- Fc epsilon receptor (FCERI) signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- FCERI mediated Ca+2 mobilization
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
|
|
- Staurosporine
- N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
- 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
- 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
- 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
- Ellagic Acid
|
|
|
|
TCF4 and PTF1A |
transcription factor 4 |
pancreas specific transcription factor, 1a |
- CDO in myogenesis
- Myogenesis
|
- Regulation of beta-cell development
- Regulation of gene expression in early pancreatic precursor cells
|
|
|
|
|
TCF4 and MSRB3 |
transcription factor 4 |
methionine sulfoxide reductase B3 |
- CDO in myogenesis
- Myogenesis
|
|
|
|
|
|
HNF1A and TLE1 |
HNF1 homeobox A |
transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) |
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- truncations of AMER1 destabilize the destruction complex
- FBXW7 Mutants and NOTCH1 in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- NOTCH1 Intracellular Domain Regulates Transcription
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by WNT in cancer
|
|
|
|
|
HNF1A and RNF14 |
HNF1 homeobox A |
ring finger protein 14 |
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
|
|
|
|
|
HNF1A and KAT2B |
HNF1 homeobox A |
K(lysine) acetyltransferase 2B |
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HATs acetylate histones
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH1
- Pre-NOTCH Expression and Processing
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- Chromatin organization
- RNA Polymerase I Transcription
- Signaling by NOTCH
- Notch-HLH transcription pathway
- NOTCH1 Intracellular Domain Regulates Transcription
- Chromatin modifying enzymes
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
|
|
|
HNF1A and GATA5 |
HNF1 homeobox A |
GATA binding protein 5 |
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
- Factors involved in megakaryocyte development and platelet production
|
|
|
|
|
HNF1B and HIST1H3A |
HNF1 homeobox B |
histone cluster 1, H3a |
- Regulation of beta-cell development
- Regulation of gene expression in early pancreatic precursor cells
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
|
- RNA Polymerase I Chain Elongation
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Mitotic Prophase
- PKMTs methylate histone lysines
- Regulatory RNA pathways
- RNA Polymerase I Promoter Clearance
- HDMs demethylate histones
- Cellular Senescence
- Signaling by Wnt
- HATs acetylate histones
- M Phase
- Amyloids
- NoRC negatively regulates rRNA expression
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- DNA methylation
- Transcriptional regulation by small RNAs
- Meiotic recombination
- HDACs deacetylate histones
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- RNA Polymerase I Transcription
- formation of the beta-catenin:TCF transactivating complex
- Epigenetic regulation of gene expression
- Senescence-Associated Secretory Phenotype (SASP)
- Negative epigenetic regulation of rRNA expression
- Factors involved in megakaryocyte development and platelet production
- PRC2 methylates histones and DNA
- Cell Cycle, Mitotic
- RMTs methylate histone arginines
- Chromatin modifying enzymes
- Oxidative Stress Induced Senescence
- TCF dependent signaling in response to WNT
- RNA Polymerase I Promoter Opening
- SIRT1 negatively regulates rRNA Expression
- Signaling by WNT in cancer
- Condensation of Prophase Chromosomes
|
|
|
|
|
TCF7L2 and UBE2I |
transcription factor 7-like 2 (T-cell specific, HMG-box) |
ubiquitin-conjugating enzyme E2I |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Peptide hormone metabolism
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Incretin synthesis, secretion, and inactivation
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
- Post-translational protein modification
- SUMOylation
- Meiotic synapsis
- Processing and activation of SUMO
- SUMO is transferred from E1 to E2 (UBE2I, UBC9)
|
|
|
|
|
TCF7L2 and CTNNBIP1 |
transcription factor 7-like 2 (T-cell specific, HMG-box) |
catenin, beta interacting protein 1 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Peptide hormone metabolism
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Incretin synthesis, secretion, and inactivation
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- deactivation of the beta-catenin transactivating complex
|
|
|
|
|
TCF7L2 and DAZAP2 |
transcription factor 7-like 2 (T-cell specific, HMG-box) |
DAZ associated protein 2 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Peptide hormone metabolism
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Incretin synthesis, secretion, and inactivation
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
|
|
|
|
|
TERF1 and WFS1 |
telomeric repeat binding factor (NIMA-interacting) 1 |
Wolfram syndrome 1 (wolframin) |
- Telomere Maintenance
- Packaging Of Telomere Ends
- DNA Damage/Telomere Stress Induced Senescence
- Chromosome Maintenance
- Cellular Senescence
- Meiotic synapsis
|
- IRE1alpha activates chaperones
- XBP1(S) activates chaperone genes
- Unfolded Protein Response (UPR)
|
|
|
|
|
NR2C2 and JAZF1 |
nuclear receptor subfamily 2, group C, member 2 |
JAZF zinc finger 1 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
|
|
|
|
|
VAV1 and PTPN22 |
vav 1 guanine nucleotide exchange factor |
protein tyrosine phosphatase, non-receptor type 22 (lymphoid) |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- FCERI mediated MAPK activation
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- CD28 co-stimulation
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- Signaling by VEGF
- Signaling by Rho GTPases
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- VEGFA-VEGFR2 Pathway
- Rho GTPase cycle
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- VEGFR2 mediated vascular permeability
- Regulation of signaling by CBL
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- Cell death signalling via NRAGE, NRIF and NADE
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- p75 NTR receptor-mediated signalling
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- CD28 dependent Vav1 pathway
- Signaling by FGFR
- NRAGE signals death through JNK
- GPVI-mediated activation cascade
- FCERI mediated Ca+2 mobilization
|
|
|
|
|
|
WFS1 and SMURF1 |
Wolfram syndrome 1 (wolframin) |
SMAD specific E3 ubiquitin protein ligase 1 |
- IRE1alpha activates chaperones
- XBP1(S) activates chaperone genes
- Unfolded Protein Response (UPR)
|
- Loss of Function of TGFBR2 in Cancer
- Antigen processing: Ubiquitination & Proteasome degradation
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- Signaling by Wnt
- TGFBR1 LBD Mutants in Cancer
- Signaling by BMP
- Hedgehog 'on' state
- Class I MHC mediated antigen processing & presentation
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- beta-catenin independent WNT signaling
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Asymmetric localization of PCP proteins
- Signaling by Hedgehog
- PCP/CE pathway
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
|
|
|
|